CERE

Cerevel Therapeutics Stock Price

34.4962
-4.35 (-11.21%)
Upgrade to Real-Time
Regular Market
34.4962

Low
9.00

52 Week Range

High
39.61

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Cerevel Therapeutics Holdings Inc CERE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-4.35 -11.21% 34.4962 11:06:34
Open Price Low Price High Price Close Price Prev Close
38.50 34.26 38.50 38.85
Bid Price Ask Price Spread News
34.47 34.53 0.06 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,038 353,784 $ 35.92 $ 12,706,550 - 9.00 - 39.61
Last Trade Time Type Quantity Stock Price Currency
11:07:21 4 $ 34.47 USD

Period:

Draw Mode:

Cerevel Therapeutics Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.00B 144.87M 52.58M $ - $ - -1.73 -19.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.53M 0.10%

more financials information »

Cerevel Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CERE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week35.0339.6134.2637.21718,324-0.5338-1.52%
1 Month27.6639.6127.3134.34545,9006.8424.72%
3 Months26.8739.6119.59525.841,066,0447.6328.38%
6 Months17.0539.6112.0126.261,308,47517.45102.32%
1 Year10.4539.619.0024.49882,10924.05230.11%
3 Years10.4539.619.0024.49882,10924.05230.11%
5 Years10.4539.619.0024.49882,10924.05230.11%

Cerevel Therapeutics Description

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.


Your Recent History
NASDAQ
CERE
Cerevel Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.